TrialJournal of hepatology2019

Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.

Gideon M Hirschfield et al.PubMed ↗Publisher ↗

No numbers read from the abstract.